AbbVie Inc. is 177.8x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($399.47 B vs $2.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RARE | ABBV |
|---|---|---|
| Market cap | $2.25 B | $399.47 B |
| US-listed rank | #2019 | #28 |
| Revenue (latest FY) | $673.00M | $61.16B |
| Net income (latest FY) | -$575.00M | $4.23B |
| Net margin | -85.4% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 1,100 | 1,008 |
AbbVie Inc. is 177.8x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($399.47 B vs $2.25 B).
In their latest fiscal years, Ultragenyx Pharmaceutical Inc. reported $673.00M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Ultragenyx Pharmaceutical Inc. and AbbVie Inc., or browse the full rankings.